UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):  May 21, 2014

 

_______________________

 

CRYOLIFE, INC.

(Exact name of registrant as specified in its charter)

_________________________

 

 

 

 

Florida

1-13165

59-2417093

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

1655 Roberts Boulevard, N.W., Kennesaw, Georgia  30144

(Address of principal executive office) (zip code)

 

Registrant's telephone number, including area code: (770) 419-3355

 

_____________________________________________________________

(Former name or former address, if changed since last report)

 

_________________________

 

      Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

 

 


 

Section 5Corporate Governance and Management

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

At CryoLife, Inc.’s (the “Company” or “CryoLife”) 2014 Annual Meeting of Stockholders held on May 21, 2014 (the “Annual Meeting”), CryoLife’s stockholders approved the CryoLife, Inc. Second Amended and Restated 2009 Stock Incentive Plan (the “Amended Plan”).  The Amended Plan became effective May 22, 2014, provides for an additional 3.0 million shares eligible for grant, and extends the duration of the plan from May 16, 2019 to May 22, 2021The terms and conditions of the Amended Plan are described in the Company’s 2014 proxy statement filed with the Securities and Exchange Commission on April 8, 2014 (the “2014 Proxy”) on pages 68 to 77, which are incorporated herein by reference.

 

On May 22, 2014,  the Company amended (the “Amendment”) its employment agreement with Steven G. Anderson, the Company’s Chairman of the Board of Directors, President and Chief Executive Officer (the “Agreement”).  The Amendment extends the term of the Agreement, which became effective January 1, 2013.  The terms and conditions of the Agreement are described in the 2014 Proxy on pages 42 to 44, which are incorporated herein by reference.    The Amendment became effective May 22, 2014, and it extends the term of the Agreement, which was set to expire according to its terms on December 31, 2015, for an additional year, through December 31, 2016.  Mr. Anderson will continue to serve as the Company’s President and Chief Executive Officer, and he will continue to serve as the Chairman of the Board of Directors of the Company, subject to the Board’s exercise of its fiduciary duties.  Except for extending the term of the Agreement, the Amendment did not modify the parties’ rights or obligations under the Agreement.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, CryoLife’s stockholders elected each individual that was nominated for election as director of the Company to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also (i) approved, by non-binding vote, the compensation paid to CryoLife’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion; (ii) approved the CryoLife, Inc. Second Amended and Restated 2009 Stock Incentive Plan; and (iii) ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2014.

The final results of the voting on each matter of business at the 2014 Annual Meeting are as follows:

Election of Directors

 

 

 

 

 

 

 

 

 

 

 

 

 

Name

  

Votes For

 

  

Votes Withheld

 

  

Broker Non-Votes

 

Steven G. Anderson

  

 

19,607,215 

  

  

 

371,087 

  

  

 

6,213,346 

  

Thomas F. Ackerman

  

 

19,671,405 

  

  

 

306,897 

  

  

 

6,213,346 

  

James S. Benson

  

 

19,624,919 

  

  

 

353,383 

  

  

 

6,213,346 

  

Daniel J. Bevevino

  

 

19,461,273 

  

  

 

517,029 

  

  

 

6,213,346 

  

Ronald C. Elkins, M.D.

  

 

18,897,627 

  

  

 

1,080,675 

  

  

 

6,213,346 

  

Ronald D. McCall, Esq.

  

 

18,801,422 

  

  

 

1,176,880 

  

  

 

6,213,346 

  

Harvey Morgan

  

 

19,624,251 

  

  

 

354,051 

  

  

 

6,213,346 

  

Jon W. Salveson

  

 

19,545,710 

  

  

 

432,592 

  

  

 

6,213,346 

  

 

Approval, by non-binding vote, of the compensation paid to CryoLife’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion

 

 

 

 

 

 

 

 

Votes For

 

Votes Against

 

Votes Abstain

 

Broker Non-Votes

18,850,564

 

852,096

 

275,642

 

6,213,346

 

 

Approval of the CryoLife, Inc. Second Amended and Restated 2009 Stock Incentive Plan

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Votes For

 

Votes Against

 

Votes Abstain

 

Broker Non-Votes

15,849,201

 

3,080,698

 

1,048,403

 

6,213,346

 

Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2014 

 

 

 

 

 

 

Votes For

 

Votes Against

 

Votes Abstain

26,018,167

 

125,655

 

47,826

 

 

-1-

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

  CRYOLIFE, INC.

 

 

 

 

 

 

Date:  May 27, 2014

By:

/s/D. A. Lee 

 

Name:

D. Ashley Lee

 

Title:

Executive Vice President, Chief

 

 

Operating Officer and Chief

 

 

Financial Officer

 

 

 

 

 

 

 

 

 

 

-2-